{"output": [["Celgene", "COMP", "Acquire", "Impact Biomedicines", "COMP"], ["Novo Nordisk", "COMP", "Offer", "Ablynx", "COMP"], ["Takeda Pharmaceutical", "COMP", "Plan_to_buy", "TiGenix", "COMP"], ["Johnson & Johnson", "COMP", "Purchase", "Actelion", "COMP"], ["Gilead", "COMP", "Acquisition", "Kite", "COMP"], ["Celgene", "COMP", "COMP", "Gilead", "COMP"], ["Celgene", "COMP", "COMP", "Johnson & Johnson", "COMP"], ["Celgene", "COMP", "COMP", "Takeda Pharmaceutical", "COMP"], ["Celgene", "COMP", "COMP", "Novo Nordisk", "COMP"], ["Biotech firms", "CONCEPT", "Discover", "Drugs of tomorrow", "CONCEPT"], ["Biotech firms", "CONCEPT", "Increasingly_pivotal_role", "Healthcare M&A", "CONCEPT"], ["Biotech groups", "CONCEPT", "Excel", "Niche disease areas", "CONCEPT"], ["Big pharma", "CONCEPT", "Looking", "Cutting-edge therapies", "CONCEPT"], ["U.S. drug approvals", "ECON_INDICATOR", "Hit", "21-year high", "ECON_INDICATOR"], ["U.S. drug approvals", "ECON_INDICATOR", "Novel medicines", "46", "ECON_INDICATOR"], ["U.S. prescriptions", "ECON_INDICATOR", "90 percent", "Generics", "ECON_INDICATOR"], ["U.S. tax changes", "EVENT", "Implementation", "U.S. tax changes", "EVENT"], ["U.S. tax overhaul", "EVENT", "Lower tax rate", "Repatriation of cash held offshore", "EVENT"], ["U.S. companies", "COMP", "Cash", "Global M&A market", "CONCEPT"], ["Case Equity Partners", "COMP", "Expect", "2018", "TIME"]], "published": "2018-01-08T17:05:00.000+02:00"}